IO Biotech (IOBT) News Today $1.74 -0.03 (-1.69%) Closing price 04:00 PM EasternExtended Trading$1.76 +0.02 (+1.15%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IOBT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period IO Biotech, Inc. (NASDAQ:IOBT) Sees Significant Growth in Short InterestAugust 19 at 3:54 PM | marketbeat.comIO Biotech Reports Q2 2025 Financial ResultsAugust 19 at 6:54 AM | msn.comIO Biotech (NASDAQ:IOBT) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPSAugust 16, 2025 | marketbeat.comIO Biotech Reports Second Quarter 2025 Financial Results and Provides Business HighlightsAugust 14, 2025 | globenewswire.comIO Biotech (NASDAQ:IOBT) Price Target Lowered to $4.00 at Morgan StanleyAugust 13, 2025 | marketbeat.comIO Biotech: A Buying Opportunity Following Phase 3 Readout In MelanomaAugust 12, 2025 | seekingalpha.comIO Biotech's Phase 3 Trial Fails To DeliverAugust 12, 2025 | seekingalpha.comIO Biotech stock rises as cancer vaccine shows promising resultsAugust 12, 2025 | investing.comIO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with ...August 12, 2025 | finance.yahoo.comIO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of ...August 12, 2025 | finance.yahoo.comIO Biotech Shares Climb Following Encouraging Cancer Vaccine Trial ResultsAugust 12, 2025 | msn.comIO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10xAugust 12, 2025 | msn.comIO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This YearAugust 12, 2025 | benzinga.comIO Biotech's cancer vaccine shows improvement, but narrowly misses study goalAugust 12, 2025 | msn.comIO Biotech's cancer vaccine shows improvement in late-stage study goalAugust 11, 2025 | reuters.comIO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly MissedAugust 11, 2025 | globenewswire.comIO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaAugust 10, 2025 | globenewswire.comIO Biotech (IOBT) Expected to Announce Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comShort Interest in IO Biotech, Inc. (NASDAQ:IOBT) Grows By 213.1%August 5, 2025 | marketbeat.comIO Biotech: Cylembio Targeting Advanced Melanoma Continues Towards Q3 PFS Data ReleaseJuly 26, 2025 | seekingalpha.comIO Biotech files to sell 4.22M shares of common stock for holdersJuly 24, 2025 | msn.comPrivate equity firms are IO Biotech, Inc.'s (NASDAQ:IOBT) biggest owners and were rewarded after market cap rose by US$16m last weekJuly 16, 2025 | finance.yahoo.comNASDAQ:IOBT Financials | IO Biotech Inc - Investing.comJuly 10, 2025 | investing.comIO Biotech (NASDAQ:IOBT) Shares Up 1.4% - Here's What HappenedJuly 9, 2025 | marketbeat.comIOBT IO Biotech, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comIO Biotech, Inc. (NASDAQ:IOBT) Short Interest Down 35.0% in MayJune 17, 2025 | marketbeat.comWall Street Zen Upgrades IO Biotech (NASDAQ:IOBT) to "Sell"June 14, 2025 | marketbeat.comCitadel Advisors LLC Purchases Shares of 270,504 IO Biotech, Inc. (NASDAQ:IOBT)June 7, 2025 | marketbeat.comIO Biotech Regains Nasdaq Compliance with Stock PriceJune 4, 2025 | msn.comIO Biotech, Inc. (NASDAQ:IOBT) Director Acquires $20,850.00 in StockJune 3, 2025 | insidertrades.comIO Biotech, Inc. (NASDAQ:IOBT) Sees Large Growth in Short InterestJune 2, 2025 | marketbeat.comHeidi Hunter Buys 15,000 Shares of IO Biotech, Inc. (NASDAQ:IOBT) StockJune 2, 2025 | marketbeat.comIO Biotech files for the sale of up to 5.6M shares of common stock for holdersMay 23, 2025 | msn.comIO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare ConferenceMay 20, 2025 | globenewswire.comQ2 Earnings Forecast for IO Biotech Issued By HC WainwrightMay 20, 2025 | marketbeat.comIO Biotech price target raised to $14 from $12 at H.C. WainwrightMay 15, 2025 | finance.yahoo.comIO Biotech Reports First Quarter 2025 Financial Results and Business HighlightsMay 14, 2025 | globenewswire.comIO Biotech unveils promising vaccine preclinical dataApril 27, 2025 | investing.comIO Biotech Presents New Preclinical Data Supporting Dual-Antigen and TGF-β-Directed Vaccines for Enhancing Anti-Tumor Immunity at AACR 2025April 27, 2025 | nasdaq.comIO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025April 26, 2025 | globenewswire.comDauntless Investment Group LLC Acquires Shares of 747,646 IO Biotech, Inc. (NASDAQ:IOBT)April 26, 2025 | marketbeat.comIO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170April 25, 2025 | globenewswire.comIO Biotech, Inc. (NASDAQ:IOBT) Short Interest Up 156.6% in MarchApril 17, 2025 | marketbeat.comWe're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn RateApril 12, 2025 | finance.yahoo.comLandscape Capital Management L.L.C. Purchases Shares of 442,196 IO Biotech, Inc. (NASDAQ:IOBT)April 10, 2025 | marketbeat.comQ1 Earnings Estimate for IO Biotech Issued By HC WainwrightApril 6, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for IO Biotech (IOBT)April 2, 2025 | markets.businessinsider.comIO Biotech (NASDAQ:IOBT) Receives "Buy" Rating from HC WainwrightApril 2, 2025 | marketbeat.comShort Interest in IO Biotech, Inc. (NASDAQ:IOBT) Increases By 54.8%March 31, 2025 | marketbeat.comIO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2025 | globenewswire.com Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address IOBT Media Mentions By Week IOBT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOBT News Sentiment▼0.680.66▲Average Medical News Sentiment IOBT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOBT Articles This Week▼32▲IOBT Articles Average Week Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rezolute News Today AnaptysBio News Today Kodiak Sciences News Today Xencor News Today Sage Therapeutics News Today Rapport Therapeutics News Today SNDL News Today Zevra Therapeutics News Today Arcturus Therapeutics News Today Savara News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IOBT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access